Link Asia International MedTech : VOLUNTARY ANNOUNCEMENT INVESTMENT COOPERATION MEMORANDUM IN RELATION TO THE POSSIBLE COOPERATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Link-Asia International MedTech Group Limited ᐑԭ਷ყᔼᐕ߅ҦණྠϞࠢʮ̡

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

VOLUNTARY ANNOUNCEMENT INVESTMENT COOPERATION MEMORANDUM IN RELATION TO THE POSSIBLE COOPERATION

This announcement is made on a voluntary basis by Link-Asia International MedTech Group Limited (the ''Company'', together with its subsidiaries, the ''Group'') on a voluntary basis to provide the shareholders (the ''Shareholders'') and potential investors of the Company with updated information in relation to the latest business development of the Group.

THE INVESTMENT COOPERATION MEMORANDUM

The board (the ''Board'') of directors of the Company (the ''Director(s)'') is pleased to announce that, on 18 March 2021 (after trading hours), Link-Asia International Cell Technology Group Limited* (環亞國際細胞科技集團有限公 司) (''Cell Technology Group''), which is a wholly-owned subsidiary of the Company, entered into a non-legally binding investment cooperation memorandum (the ''Memorandum'') with Hanguang Technology (Shanghai) Gene Technology Co., Ltd* (漢光雲科（上海）生物醫藥科技有限公 司 )( ''Hanguang Technology''), pursuant to which Cell Technology Group and Hanguang Technology agreed to cooperate and form a joint venture company (the ''JV Company'') for the purpose of engaging in the business of endometrial stem cell storage and fertility health management (the ''Possible Cooperation'').

According to the Memorandum, Cell Technology Group will hold majority of the equity interest in the JV Company upon completion of its formation. Besides, Mr. Wang Xuejun (王學軍 )( ''Mr. Wang'') will be appointed as the management of the JV Company, who will be responsible for the daily operation and management of the JV Company.

Within 60 days from the date of signing of the Memorandum, Cell Technology Group shall conduct a due diligence review on Hanguang Technology. Subject to the completion of the due diligence review and the results of the aforesaid due diligence review being satisfied to Cell Technology Group, Cell Technology Group and Hanguang Technology shall enter into a formal investment cooperation agreement to stipulate the details of the formation of the JV Company.

INFORMATION ABOUT HANGUANG TECHNOLOGY

Hanguang Technology is a company established in the People's Republic of China (''PRC'') with limited liability and the principal business of its group is stem cell and regenerative medicine technology research and storage management.

According to the information provided by Hanguang Technology, as at the date of the announcement, Hanguang Technology is owned by an individual, Zhongkang Regenerative Medicine Technology (Hainan) Co., Ltd (中康再生醫學科技(海南)有限公司 )( ''Zhongkang Regenerative'') and another limited liability company registered in PRC, which hold 59%, 21%, 20% of equity interests, respectively. 40% equity interests of Zhongkang Regenerative is held by Dr. Sun Xiaohu, an independent non-executive Director of the Company.

To the best of knowledge, information and belief of the Directors having made all reasonable inquiries, save as disclosed above, as at the date of this announcement, Hanguang Technology and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the ''Listing Rules'')). Since Hanguang Technology is not a 30% controlled company directly or indirectly held by Zhongkang Regenerative, according to Chapter 14A of the Listing Rules, the Possible Cooperation does not constitute a connected transaction.

INFORMATION ABOUT MR. WANG

Mr. Wang holds a master's degree in business administration from Nankai University. Mr. Wang has extensive experience in the stem cell industry. Based on the information provided by Mr. Wang, he served as an executive director and chief executive officer of China Regenerative Medicine International Limited, whose shares are listed on the GEM of The Stock Exchange of Hong Kong Limited (stock code: 8158). Besides, Mr. Wang was also an executive deputy general manager of Zhongyuan Xiehe cell genetic engineering Co., Ltd., whose shares are listed on Shanghai Stock Exchange (stock code: 600645), and he was the general manager of Heze Biotechnology Co., Ltd.

REASONS FOR AND BENEFITS OF THE POSSIBLE COOPERATION

The Group is principally engaged in (i) electronic manufacturing services; (ii) marketing and distribution of communication products; (iii) real estate supply chain services; and (iv) the securities and other assets investment.

In view of the challenges bringing from the novel coronavirus disease, the Board and the management of the Company are not only dedicated to developing the Group's existing core businesses but are actively exploring new business growth, especially the assisted reproductive medical technology business with huge market demand.

According to the relevant research, female endometrial stem cells can be widely used in the treatment of various gynecological diseases and have a promising prospect of clinical application, including premature ovarian failure, intrauterine adhesions, endometriosis, infertility, endometrial hyperplasia, endometrial cancer, etc. The storage and management of endometrial stem cells can provide an important guarantee for the treatment of infertility diseases and help the development of assisted reproductive business.

The Board believes that through (i) the establishment of the JV Company with strategic partners; (ii) the introduction of a management team with rich experience in the development and application of biotechnology; and (iii) the introduction of technological innovation, the Group could consolidate its layout in the industry of assisted reproductive technology and cell technology, which, if materialise, could help the Group to restructure its business to an industry with growth potential.

GENERAL

The Board wishes to emphasise that as at the date of this announcement, the Company has not entered into a legally binding agreement in relation to the proposed formation of the JV Company. The Possible Cooperation, if materialised, may constitute a notifiable transaction for the Company under the Listing Rules. Further announcement(s) will be made by the Company as and when appropriate in compliance with the Listing Rules.

Shareholders and other investors of the Company should note that the Possible Cooperation may or may not proceed and are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board

Link-Asia International MedTech Group Limited

Lin Dailian

Chairman and executive Director

Hong Kong, 18 March 2021

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Dr. Sun Xiaohu as independent non-executive Directors.